FiercePharma8d
Axsome secures hard-fought FDA nod for rapid-acting migraine drug Symbravo
Meloxicam is a nonsteroidal, anti-inflammatory molecule developed with Axsome’s Molecular Solubility Enhanced Inclusion ...
US FDA approves Axsome Therapeutics' migraine drug
The U.S. Food and Drug Administration has approved Axsome Therapeutics' migraine treatment, the company said on Thursday.
FDA approves Symbravo for acute treatment of migraine in adults
The U.S. Food and Drug Administration has approved Axsome Therapeutics' Symbravo (meloxicam and rizatriptan) for the acute ...
Pharm Exec7d
FDA Approves Axsome Therapeutics’ Symbravo for Migraine with or without Aura
Clinical trials demonstrated that a single dose of Symbravo provides rapid migraine relief, sustains efficacy for up to 48 ...
BioSpace8d
Axsome’s Migraine Medicine Clears FDA Bar
The approval of Axsome Therapeutics’ Symbravo for migraine with or without aura came alongside the greenlight for Vertex's ...
Axsome Gets FDA Nod for New Migraine Drug Symbravo, Stock Rises
The FDA approves AXSM's Symbravo for the acute treatment of migraine with or without aura in adults. The latest nod diversifies its commercial portfolio.
Investing8d
FDA approves Axsome's novel migraine treatment SYMBRAVO
In other recent news, Axsome Therapeutics, a biopharmaceutical company, announced that the FDA has approved SYMBRAVO®, a novel treatment for migraines in adults. The approval was based on results ...
Axsome Therapeutics’ Promising Market Potential Following FDA Approval of Symbravo for Acute Migraine
Analyst Vikram Purohit of Morgan Stanley maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report), retaining the price target of ...
MedPage Today7d
Acute Migraine Treatment Gets a New Drug
The FDA approved an oral combination of meloxicam and rizatriptan (Symbravo) to treat adults with acute migraine with or ...